Nucorion Pharmaceuticals, Inc. is a venture-funded biotechnology company focused on developing anti-cancer and anti-viral agents targeted at diseases of the liver, initially directed to the Chinese market. Nucorion was co-founded by Ligand and Professor Zucai Suo of The Ohio State University (OSU), who also chairs Nucorion’s Scientific Advisory Board (SAB). In addition to Dr. Suo, Nucorion’s SAB includes: Jack W. Szostak Ph.D. - 2009 Nobel Laureate, Howard Hughes Medical Institute Investigator and Professor of Genetics at Harvard Medical School; Stephen J. Benkovic, Ph.D. - 2010 National Medal of Science recipient and Eberly Chair of Chemistry at Pennsylvania State University; John Kozarich, Ph.D. - Ligand Pharmaceuticals Chairman and ActivX Biosciences Chairman and President; and Lin Zhi, Ph.D. - Ligand Pharmaceuticals Vice President of Chemistry and Pharmaceutical Sciences. Nucorion has rights to certain programs leveraging the LTP technology as well as rights to certain novel analog compounds licensed from OSU. Nucorion is majority owned and funded by Silver River International Investment Ltd. Ligand is a minority shareholder of Nucorion, currently owning less than 20%. For additional information, visit www.nucorionpharma.com.
Please click here for clinical trial information.